- ICH GCP
- Реестр клинических исследований США
- Клиническое испытание NCT04968912
Исследование нипокалимаба у взрослых с первичным синдромом Шегрена (ПСС)
Рандомизированное плацебо-контролируемое двойное слепое многоцентровое исследование по оценке эффективности и безопасности нипокалимаба у взрослых с первичным синдромом Шегрена (ПСШ)
The purpose of this study is to evaluate the efficacy and safety of nipocalimab in participants with primary Sjogren's syndrome (pSS) versus placebo.
Обзор исследования
Статус
Условия
Вмешательство/лечение
Тип исследования
Регистрация (Действительный)
Фаза
- Фаза 2
Расширенный доступ
Контакты и местонахождение
Места учебы
-
-
-
Berlin, Германия, 10117
- Charite Universitaetsmedizin Berlin
-
Cologne, Германия, 50923
- Uniklinik Köln
-
Dresden, Германия, 01307
- Universitatsklinikum Carl Gustav Carus Dresden
-
Hamburg, Германия, 20095
- Hamburger Rheuma Forschungszentrum II
-
Kirchheim unter Teck, Германия, 73230
- medius KLINIK KIRCHHEIM
-
Tübingen, Германия, 72076
- Universitatsklinikum Tubingen
-
-
-
-
-
A Coruña, Испания, 15006
- Hosp Univ A Coruna
-
Córdoba, Испания, 14004
- Hosp Reina Sofia
-
Mérida, Испания, 6800
- Hosp. de Merida
-
Sabadell, Испания, 08208
- Corporacio Sanitari Parc Tauli
-
Salamanca, Испания, 37007
- Hosp Clinico Univ de Salamanca
-
Seville, Испания, 41010
- Hosp. Infanta Luisa
-
-
-
-
-
Brescia, Италия, 25123
- Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia Presidio Spedali Civili
-
Catania, Италия, 95100
- P.O. Vittorio Emanuele Azienda Ospedaliero Universitaria 'Policlinico Vittorio Emanuele'
-
Milan, Италия, 20132
- IRCCS Ospedale San Raffaele
-
Palermo, Италия, 90129
- Azienda Ospedaliero Universitaria Policlinico Paolo Giaccone
-
Verona, Италия, 37126
- Azienda Ospedaliera Universitaria Integrata Verona
-
-
-
-
-
Leeuwarden, Нидерланды, 8934 AD
- Medisch Centrum Leeuwarden
-
Rotterdam, Нидерланды, 3015 GD
- Erasmus Medisch Centrum
-
-
-
-
-
Bydgoszcz, Польша, 85-065
- Nasz Lekarz Przychodnie Medyczne
-
Bydgoszcz, Польша, 85-168
- Szpital Uniwersytecki nr 2 im dr Jana Biziela w Bydgoszczy
-
Gmina Końskie, Польша, 26 200
- Zespolu Opieki Zdrowotnej w Konskich
-
Krakow, Польша, 30-002
- Malopolskie Badania Kliniczne Sp z o o
-
Lublin, Польша, 20-607
- REUMED Zespol Poradni Specjalistycznych Filia nr 2
-
Poznan, Польша, 61 113
- Centrum Medyczne
-
Warsaw, Польша, 00-874
- Medycyna Kliniczna
-
Warsaw, Польша, 02 637
- Narodowy Instytut Geriatrii Reumatologii i Rehabilitacji im prof dr hab med Eleonory Reicher
-
Warsaw, Польша, 03 291
- Centrum Medyczne AMED Targowek
-
Wroclaw, Польша, 52 415
- Centrum Medyczne Oporow
-
-
-
-
-
Lisbon, Португалия, 1050-034
- Instituto Portugues de Reumatologia
-
Ponte de Lima, Португалия, 4990-078
- ULSAM, EPE - Hospital Conde de Bertiandos
-
-
-
-
Alabama
-
Anniston, Alabama, Соединенные Штаты, 36207
- Anniston Medical Clinic
-
-
Arizona
-
Glendale, Arizona, Соединенные Штаты, 85306
- Arizona Arthritis and Rheumatology Research PLLC
-
Mesa, Arizona, Соединенные Штаты, 85210
- Arizona Arthritis & Rheumatology Research, PLLC
-
-
California
-
Fullerton, California, Соединенные Штаты, 92835
- St. Jude Heritage Medical Group
-
Upland, California, Соединенные Штаты, 91786
- Inland Rheumatology Clinical Trials, Inc.
-
-
Colorado
-
Denver, Colorado, Соединенные Штаты, 80230
- Denver Arthritis Clinic
-
Denver, Colorado, Соединенные Штаты, 80228
- Colorado Arthritis Associates
-
-
Florida
-
Boca Raton, Florida, Соединенные Штаты, 33486
- Rheumatology Associates Of South Florida
-
Brandon, Florida, Соединенные Штаты, 33511
- Bay Area Arthritis and Osteoporosis
-
Fort Lauderdale, Florida, Соединенные Штаты, 33309
- Centre for Rheumatology, Immunology and Arthritis
-
Jacksonville, Florida, Соединенные Штаты, 32209
- University of Florida Health Jacksonville
-
Orlando, Florida, Соединенные Штаты, 32835
- Omega Research Consultants
-
-
Illinois
-
Gurnee, Illinois, Соединенные Штаты, 60031
- Clinical Investigation Specialists
-
-
Iowa
-
Iowa City, Iowa, Соединенные Штаты, 52242
- University of Iowa Hospitals and Clinics
-
-
Kansas
-
Kansas City, Kansas, Соединенные Штаты, 66160
- University of Kansas Medical Center
-
-
Minnesota
-
Eagan, Minnesota, Соединенные Штаты, 55121
- St. Paul Rheumatology P A
-
-
Mississippi
-
Tupelo, Mississippi, Соединенные Штаты, 38801
- North Mississippi Medical Clinics
-
-
North Carolina
-
Salisbury, North Carolina, Соединенные Штаты, 28144
- PMG Research of Salisbury
-
-
Pennsylvania
-
Duncansville, Pennsylvania, Соединенные Штаты, 16635
- Altoona Center For Clinical Research
-
Philadelphia, Pennsylvania, Соединенные Штаты, 19104
- University of Pennsylvania
-
-
South Carolina
-
Columbia, South Carolina, Соединенные Штаты, 29204
- Columbia Arthritis Center
-
-
Tennessee
-
Jackson, Tennessee, Соединенные Штаты, 38305
- West Tennessee Research Institute
-
Memphis, Tennessee, Соединенные Штаты, 38119
- Dr. Ramesh Gupta
-
-
Texas
-
Austin, Texas, Соединенные Штаты, 78731-3146
- Austin Regional Clinic
-
Carrollton, Texas, Соединенные Штаты, 75007
- Trinity Clinical Research, LLC
-
-
-
-
-
Taipei, Тайвань, 11490
- Tri-Service General Hospital
-
Taoyuan, Тайвань, 333
- Chang Gung Memorial Hospital Linkou Branch
-
-
-
-
-
La Tronche, Франция, 38700
- CHU de Grenoble Hopital Albert Michallon
-
Le Mans, Франция, 72037
- Centre Hospitalier Le Mans
-
Marseille, Франция, 13285
- Hopital Saint Joseph
-
Paris, Франция, 75013
- Hopital Pitie Salpetriere
-
Strasbourg, Франция, 67098
- CHRU Hôpital de Hautepierre
-
-
-
-
-
Fuchū, Япония, 183 8524
- Tokyo Metropolitan Tama Medical Center
-
Nagasaki, Япония, 852-8501
- Nagasaki University Hospital
-
Sapporo, Япония, 060-8648
- Hokkaido University Hospital
-
Tokyo, Япония, 104 8560
- St. Luke's International Hospital
-
Tokyo, Япония, 173 8610
- Nihon University Itabashi Hospital
-
Tsukuba, Япония, 305-8520
- University of Tsukuba Hospital
-
-
Критерии участия
Критерии приемлемости
Возраст, подходящий для обучения
Принимает здоровых добровольцев
Полы, имеющие право на обучение
Описание
Inclusion Criteria:
- Meets classification criteria for primary Sjogren's syndrome (pSS) by the 2016 American College of Rheumatology (ACR) / European League Against Rheumatism (EULAR) at the time of screening (results either obtained during screening or documented in the participant's medical history are acceptable to fulfill these criteria for Schirmer's test, unstimulated salivary flow test, ocular staining score, or labial salivary gland biopsy), and was diagnosed with pSS no less than 26 weeks prior to screening
- At screening is seropositive for antibodies to pSS-associated antigen A (Ro/Sjogren's syndrome-related antigen A [SSA])
- Total Clinical European League Against Rheumatism Sjogren's Syndrome Disease Activity Index (clinESSDAI) score greater than or equal to (>=) 6
- At least one abnormal laboratory marker of pSS-related inflammatory disease activity, and at least low activity in one or more specified European League Against Rheumatism Sjogren's Syndrome Disease Activity Index (ESSDAI) domains
- It is recommended to be up to date on all age-appropriate vaccinations prior to screening per routine local medical guidelines. It is strongly recommended that participants will have completed a locally-approved (or emergency use-authorized) coronavirus disease 2019 (COVID-19) vaccination regimen at least 2 weeks prior to study related visits or procedures. Study participants should, follow applicable local vaccine labelling, guidelines, and standards-of-care for participants receiving immune-targeted therapy will be followed when determining an appropriate interval between vaccination and study enrollment
Exclusion Criteria:
- Has any confirmed or suspected clinical immunodeficiency syndrome not related to treatment of his/her pSS or has a family history of congenital or hereditary immunodeficiency unless confirmed absent in the participant
- Comorbidities (for example, asthma, chronic obstructive pulmonary disease) which have required 3 or more courses of systemic glucocorticoids within the previous 12 months
- Has any unstable or progressive manifestation of pSS that is likely to warrant escalation in therapy beyond permitted background medications and/or has severely active pSS
- Has received oral cyclophosphamide within 3 months or intravenous (IV) cyclophosphamide within 6 months prior to first administration of study intervention
- Has Sjogren's syndrome overlap syndromes where another confirmed autoimmune rheumatic or systemic inflammatory condition (for example, rheumatoid arthritis [RA], systemic lupus erythematosus [SLE], scleroderma, inflammatory bowel disease [IBD]) is the primary diagnosis or has clinical manifestations that, in the opinion of the investigator, or the sponsor or sponsor's representative, are likely to interfere with the investigator's ability to assess pSS manifestations
Учебный план
Как устроено исследование?
Детали дизайна
- Основная цель: Другой
- Распределение: Рандомизированный
- Интервенционная модель: Параллельное назначение
- Маскировка: Двойной
Оружие и интервенции
Группа участников / Армия |
Вмешательство/лечение |
|---|---|
|
Плацебо Компаратор: Group 1: Placebo
Participants will receive placebo intravenously (IV) every 2 weeks (q2w) through Week 22 along with standard of care treatments ([including ophthalmic drops, artificial tears and saliva, punctum plugs, and secretagogues], and/or one immunomodulator with or without low-dose glucocorticosteroids). |
Placebo infusion will be administered intravenously. Standard of care treatment including ophthalmic drops, artificial tears and saliva, punctum plugs, and secretagogues, and/or one immunomodulator with or without low-dose glucocorticosteroids will be administered topically/orally. |
|
Экспериментальный: Group 2: Nipocalimab Dose 1
Participants will receive nipocalimab dose 1 IV q2w through Week 22 along with standard of care treatments ([including ophthalmic drops, artificial tears and saliva, punctum plugs, and secretagogues], and/or one immunomodulator with or without low-dose glucocorticosteroids). |
Standard of care treatment including ophthalmic drops, artificial tears and saliva, punctum plugs, and secretagogues, and/or one immunomodulator with or without low-dose glucocorticosteroids will be administered topically/orally. Nipocalimab dose 1 and dose 2 infusions will be administered intravenously.
Другие имена:
|
|
Экспериментальный: Group 3: Nipocalimab Dose 2
Participants will receive nipocalimab dose 2 IV q2w through Week 22 along with standard of care treatments ([including ophthalmic drops, artificial tears and saliva, punctum plugs, and secretagogues], and/or one immunomodulator with or without low-dose glucocorticosteroids). |
Standard of care treatment including ophthalmic drops, artificial tears and saliva, punctum plugs, and secretagogues, and/or one immunomodulator with or without low-dose glucocorticosteroids will be administered topically/orally. Nipocalimab dose 1 and dose 2 infusions will be administered intravenously.
Другие имена:
|
Что измеряет исследование?
Первичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Change From Baseline in Clinical European League Against Rheumatism (EULAR) Sjögren's Syndrome Disease Activity Index (clinESSDAI) Score at Week 24
Временное ограничение: Baseline (Week 0), Week 24
|
In clinESSDAI, physician scores systemic disease activity level on 11 organ-specific domains (constitutional, lymphadenopathy, lymphoma, articular, muscular, cutaneous, glandular, pulmonary, renal, peripheral nervous system, central nervous system, and hematological), with each domain activity in 3 to 4 levels (no, low, moderate, high) according to their severity as assessed by investigator based on pre-defined criteria. The activity-level score ranges from 0 to 3, where 0=no disease activity and 3=high disease activity. Not all domain include all 4 activity level. Each domain was assigned weight between 1 and 7; activity-level score is multiplied by corresponding domain weight to obtain weighted domain score. Each domain has specific scoring range determined by its activity level and assigned weight. Sum of weighted domain score is overall score, which range from 0 to 135, where lower score=no symptom and higher score=severe symptom. A decrease from baseline indicated improvement. |
Baseline (Week 0), Week 24
|
Вторичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Change From Baseline in EULAR Sjögren's Syndrome Patient Reported Index (ESSPRI) Score at Week 24
Временное ограничение: Baseline (Week 0), Week 24
|
Change from baseline in ESSPRI score at Week 24 was reported. The ESSPRI was a patient-reported assessment of the severity of dryness, fatigue, and pain associated with primary Sjögren's Syndrome. Participants were asked to rate the severity of dryness, fatigue and pain over the past 2 weeks on a numeric rating scale (NRS), ranging from 0 "no symptom" to 10 "maximal imaginable" symptoms (dryness, fatigue, pain). Each domain was scored on scale of 0 to 10 (0 = no symptom at all and 10 = worst symptom imaginable). A total score was calculated as the mean of the 3 individual domain scores, where all domains carry the same weight. Minimum score can be 0 and maximum score can be 10, where higher ESSPRI scores indicated more severe symptoms. |
Baseline (Week 0), Week 24
|
|
Percentage of Participants With Improvement of Greater Than or Equal to (>=) 4 Points From Baseline in EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) Score at Week 24
Временное ограничение: Baseline (Week 0), Week 24
|
ESSDAI covers 11 organ-specific domain (constitutional, lymphadenopathy and lymphoma, articular, muscular, cutaneous, glandular, pulmonary, renal, peripheral nervous system, central nervous system, hematological) and 1 biological domain. Activity in each domain was scored at 3 to 4 level (no/low/moderate/high) according to severity as assessed by investigator based on criteria. Activity-level score range from 0 to 3 (0=no activity, 3=high activity; not all domain have 4 activity level). Each domain was assigned weight range from 1 to 6. Activity-level score was multiplied by corresponding domain weight to get weighted domain score. Each domain had specific scoring range determined by its activity level and assigned weight. Sum of weighted domain score was overall ESSDAI score, ranging from 0 to 123 (0=no systemic disease activity, higher score indicated greater systemic disease activity). Decrease from baseline meant improvement. |
Baseline (Week 0), Week 24
|
|
Percentage of Participants With Improvement of >= 4 Points From Baseline in clinESSDAI Score at Week 24
Временное ограничение: Baseline (Week 0), Week 24
|
In clinESSDAI, physician score systemic disease activity level on 11 organ-specific domain (constitutional, lymphadenopathy and lymphoma, articular, muscular, cutaneous, glandular, pulmonary, renal, peripheral nervous system, central nervous system, and hematological), with each domain activity in 3 to 4 level (no/low/moderate/high) according to their severity assessed by investigator based on predefined criteria. Activity-level score range from 0 to 3 (0=no activity, 3=high activity; not all domain include 4 activity level). Each domain was assigned weight from 1 to 7; activity-level score was multiplied by corresponding domain weight to get weighted domain score. Each domain had specific scoring range determined by its activity level and assigned weight. Sum of weighted domain score was overall score ranging from 0 to 135 (lower score=no symptom, higher score=severe symptom). Decrease from baseline indicated improvement. |
Baseline (Week 0), Week 24
|
|
Percentage of Participants With ESSPRI Response Defined as a Decrease of One Point or a Decrease of >= 15 Percent (%) in the ESSPRI Score From Baseline at Week 24
Временное ограничение: Baseline (Week 0), Week 24
|
Percentage of participants with ESSPRI response defined as a decrease of one point or a decrease of >= 15% from baseline at Week 24 was reported. The ESSPRI was a patient-reported assessment of the severity of dryness, fatigue, and pain associated with primary Sjogren's syndrome. Participants were asked to rate the severity of dryness, fatigue and pain over the past 2 weeks on a numeric rating scale (NRS), ranging from 0 "no symptom" to 10 "maximal imaginable" symptoms (dryness, fatigue, pain). Each domain was scored on scale of 0 to 10 (0 = no symptom at all and 10 = worst symptom imaginable). A total score was calculated as the mean of the 3 individual domain scores, where all domains carry the same weight. Minimum score can be 0 and maximum score can be 10, where higher ESSPRI scores indicated more severe symptoms. |
Baseline (Week 0), Week 24
|
|
Percentage of Participants With Disease Response According to the Sjögren's Tool for Assessing Response (STAR) Composite Score at Week 24
Временное ограничение: At Week 24
|
Percentage of participants with disease response according to STAR composite score at Week 24 was reported. STAR was a composite endpoint assessing multiple clinically relevant disease features. A STAR response was defined as a composite score of >=5 points in the 5 STAR domains, with weighting in parentheses: (i) decrease of >=3 in clinESSDAI score (3), (ii) decrease of >=1 point or >=15% from baseline in ESSPRI score (3), (iii) abnormal Schirmer's test at baseline and increase of >=5 millimeter (mm)/normal Schirmer's test at baseline and no change to abnormal/abnormal ocular staining score at baseline and a decrease of >=2 points/normal ocular staining score at baseline and no change to abnormal (1), (iv) increase of >=25% in unstimulated whole saliva/any increase if score is 0 at baseline (1), (v) decrease of >=25% in rheumatoid factor/decrease of >=10% in immunoglobulin G (IgG) (1). Overall score was sum of all domain weight, which range from 0 to 9 (higher score = worse outcome). |
At Week 24
|
|
Percentage of Participants With an Improvement in Disease Activity Level (DAL) by >= 1 Level in at Least One clinESSDAI or ESSDAI Domain at Week 24
Временное ограничение: At Week 24
|
DAL=level of disease activity severity (no/low/moderate/severe) in each clinESSDAI/ESSDAI domain. In clinESSDAI, physician score DAL on 11 organ-specific domains (constitutional, lymphadenopathy, lymphoma, articular, muscular, cutaneous, glandular, pulmonary, renal, peripheral and central nervous system, hematological) with each domain activity in 3-4 level according to severity (0=no activity, 3=high activity; not all domains have 4 activity level). Each domain given weight: 1-7, activity level score * domain weight. Sum of weighted domain score was overall score (0-135: higher score=severe symptom). A decrease from baseline indicated improvement. Participants with improvement of >= 4 points (minimal clinically important improvement) were reported in this outcome measure. ESSDAI differs from clinESSDAI by adding biological domain that cover B-cell biomarker (elevated gamma-globulin/IgG level, low complement level, cryoglobulinemia, monoclonal gammopathy). |
At Week 24
|
|
Percentage of Participants With Improvement From Baseline in >= 3 of 5 Composite of Relevant Endpoints for Sjögren's Syndrome (CRESS) Categories at Week 24
Временное ограничение: At Week 24
|
Percentage of participants with improvement from baseline in >= 3 of 5 CRESS categories at Week 24 was reported. CRESS was a composite tool that incorporates measures of disease activity (clinESSDAI), symptoms (ESSPRI), glandular function and systemic inflammation to assess disease activity. A CRESS response was defined as a response in >= 3 of the following 5 categories: (i) clinESSDAI score less than (<) 5 (low disease activity), (ii) decrease of >= 1 point or >= 15% from baseline in ESSPRI score, (iii) abnormal Schirmer's test at baseline (<= 5 mm) and an increase of >= 5 mm, or normal Schirmer's test at baseline and no change to abnormal, (iv) increase of >= 25% in unstimulated whole saliva or any increase if score is 0 at baseline, (v) decrease of >= 25% in rheumatoid factor or decrease of >= 10% in IgG. |
At Week 24
|
|
Number of Participants With Treatment-emergent Adverse Events (TEAEs) Through End of Study Visit
Временное ограничение: Post first administration of study intervention (Week 0) up to Week 30
|
An adverse event (AE) was any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non investigational) product. An AE does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. TEAEs were defined as AEs with onset or worsening on or after date of first dose of study treatment. |
Post first administration of study intervention (Week 0) up to Week 30
|
|
Number of Participants With Treatment-emergent Adverse Events of Special Interests (AESIs) Through End of Study Visit
Временное ограничение: Post first administration of study intervention (Week 0) up to Week 30
|
Number of participants with AESIs were reported. AEs was any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product. Treatment-emergent adverse events associated with the following situations were considered AESIs. (i) Infections that were severe or require IV anti-infective or operative/invasive intervention; (ii) Hypoalbuminemia with albumin < 20 grams per liter (g/L) (< 2.0 grams per deciliter [g/dL]); applicable to participants who had albumin greater than (>) 20 g/L at previous assessments. Those who entered with < 20 g/L and stayed below this level were not reported as an AESI. Those who entered with an albumin > 20 g/L or those who entered with albumin < 20g/L and then had an increase in albumin > 20 g/L which subsequently decreased to < 20 g/L were reported as an AESI. |
Post first administration of study intervention (Week 0) up to Week 30
|
|
Number of Participants With Treatment-emergent Serious Adverse Events (SAEs) Through End of Study Visit
Временное ограничение: Post first administration of study intervention (Week 0) up to Week 30
|
A SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/ incapacity; congenital anomaly or any situation deemed medically important by the investigator. Treatment-emergent SAEs were defined as SAEs with onset or worsening on or after date of first dose of study treatment. |
Post first administration of study intervention (Week 0) up to Week 30
|
|
Number of Participants With TEAEs Leading to Treatment Discontinuation Through End of Study Visit
Временное ограничение: Post first administration of study intervention (Week 0) up to Week 30
|
Number of participants with TEAEs leading to treatment discontinuation were reported. AEs was any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product. TEAEs are defined as AEs with onset or worsening on or after date of first dose of study treatment. |
Post first administration of study intervention (Week 0) up to Week 30
|
|
Number of Participants With Clinically Significant Abnormalities in Vital Signs
Временное ограничение: Post first administration of study intervention (Week 0) up to Week 30
|
Number of participants with clinically significant abnormalities in vital signs were reported. Vital signs parameters including temperature (< 36 degree Celsius and > 38 degree Celsius), pulse rate (<= 50 beats per minute [bpm] and with >= 15 bpm decrease from baseline and >= 120 bpm and with >= 15 bpm increase from baseline), and blood pressure (systolic blood pressure [SBP]: <= 90 millimeters of mercury [mmHg] and with >= 20 mmHg decrease from baseline and >= 160 mmHg and with >= 20 mmHg increase from baseline; diastolic blood pressure [DBP]: <= 50 mmHg and with >= 15 mmHg decrease from baseline and >= 100 mmHg and with >= 15 mmHg increase from baseline). Only those categories in which at least 1 participant had data were reported. |
Post first administration of study intervention (Week 0) up to Week 30
|
|
Number of Participants With Clinically Significant Abnormalities in Laboratory Parameters
Временное ограничение: Weeks 2, 4, 8, 12, 16, 20, 24, and 30
|
Laboratory parameters included hematology (platelet count [platelets: decrease > 20% and value < 100)], red blood cell count, hemoglobin, hematocrit, white blood cell count with differential [lymphocytes: decrease > 20% and value < 0.08], [leukocytes: decrease > 10% and value < 2.5], [neutrophils: increase > 30% and value > 0.90], [eosinophils: increase > 20% and value > 0.10]), serum chemistry (phosphate [decrease > 10% and value < 0.6), lipid panel (high-density lipoprotein [HDL] and low-density lipoprotein [LDL], creatine kinase: increase > 20% and value > 960, cholesterol: value >= 6.2), urinalysis, and blood coagulation. Participants were assessed at Weeks 2, 4, 8, 12, 16, 20, 24, 30 but only those categories and timepoints (Weeks 2, 4, 8, 12, 16, 24, 30) in which at least 1 participant had data were reported. |
Weeks 2, 4, 8, 12, 16, 20, 24, and 30
|
|
Serum Nipocalimab Concentration Over Time
Временное ограничение: Predose and postdose at Weeks 0, 2, 8, and 12, predose at Weeks 4, 16, 24, and 30
|
Serum concentrations of nipocalimab over time was reported. This outcome measure was planned to be analyzed for specified arms only. |
Predose and postdose at Weeks 0, 2, 8, and 12, predose at Weeks 4, 16, 24, and 30
|
|
Change From Baseline in C-reactive Protein (CRP)
Временное ограничение: Baseline (Week 0), Weeks 2, 4, 6, 8, 10, 12, 16, 20, 24, and 30
|
Change from baseline in CRP were reported. |
Baseline (Week 0), Weeks 2, 4, 6, 8, 10, 12, 16, 20, 24, and 30
|
|
Change From Baseline in Erythrocyte Sedimentation Rate (ESR)
Временное ограничение: Baseline (Week 0), Weeks 2, 4, 8, 12, 16, 20, 24, and 30
|
Change from baseline in ESR were reported. ESR was a composite outcome assessment that measures the degree of inflammation. |
Baseline (Week 0), Weeks 2, 4, 8, 12, 16, 20, 24, and 30
|
|
Change From Baseline in Total Immunoglobulin (Ig)G, IgG1, IgG2, IgG3, IgG4
Временное ограничение: Baseline (Week 0), Weeks 2, 4, 8, 12, 16, 20, 24, and 30
|
Change from baseline in total IgG, IgG1, IgG2, IgG3, IgG4 were reported. |
Baseline (Week 0), Weeks 2, 4, 8, 12, 16, 20, 24, and 30
|
|
Change From Baseline in Autoantibodies : Anti-Sjogren's Syndrome Related Antigen A (Anti-Ro/SSA), Anti-Sjogren's Syndrome Related Antigen B (Anti-La/SSB), and Anti-Ro52/TRIM21
Временное ограничение: Baseline (Week 0), Weeks 2, 4, 8, 16, 24, and 30
|
Change from baseline in autoantibodies included anti-Ro60/SSA, anti-La/SSB, and anti-Ro52/tripartite motif-containing protein 21 (Anti-Ro52/TRIM21) were reported. |
Baseline (Week 0), Weeks 2, 4, 8, 16, 24, and 30
|
|
Change From Baseline in Autoantibodies: Rheumatoid Factor (RF)
Временное ограничение: Baseline (Week 0), Weeks 2, 4, 8, 12, 16, 20, 24, and 30
|
Change from baseline in autoantibodies included RF were reported. |
Baseline (Week 0), Weeks 2, 4, 8, 12, 16, 20, 24, and 30
|
|
Number of Participants With Anti-drug Antibodies (ADAs) to Nipocalimab
Временное ограничение: Baseline (Week 0) up to Week 30
|
Number of participants with ADA to nipocalimab were reported. The presence of ADA to nipocalimab in serum was determined by a sensitive and drug-tolerant electrochemiluminescence immunoassay (ECLIA) method. This outcome measure was planned to be analyzed for specified arms only. |
Baseline (Week 0) up to Week 30
|
|
Number of Participants With Neutralising Antibodies (NAbs) to Nipocalimab
Временное ограничение: Baseline (Week 0) up to Week 30
|
Number of participants with NAbs were reported. Neutralising antibodies to nipocalimab were assessed using a non-cell based competitive ligand binding ECLIA assay. This outcome measure was planned to be analyzed for specified arms only. |
Baseline (Week 0) up to Week 30
|
Соавторы и исследователи
Следователи
- Директор по исследованиям: Janssen Research & Development, LLC Clinical Trial, Janssen Research & Development, LLC
Публикации и полезные ссылки
Общие публикации
- Yu F, Myshkin E, Nguyen B, Bobadilla Mendez C, Cossu M, Fei K, Wang Q, Hubbard JJ, Campbell K, Ramchandren S, Rojo Cella R, Edwards R, Taylor PC, Gottenberg JE, Noaiseh G, Vu T, Antozzi C, Winthrop KL, Cuff CA, Loza MJ, Dimitrova D, Gao S. Effect of nipocalimab on IgG responses to vaccinations and viral infections in patients with IgG autoantibody-mediated diseases: Post hoc analyses of three randomized, placebo-controlled trials. Hum Vaccin Immunother. 2026 Dec;22(1):2664331. doi: 10.1080/21645515.2026.2664331. Epub 2026 May 5.
- Noaiseh G, Sivils KL, Campbell K, Idokogi J, Lo KH, Liva SG, Leu JH, Dhatt H, Ma K, Leonardo S, Li H, Hubbard JJ, Gottenberg JE. Efficacy and safety of nipocalimab in patients with moderate-to-severe Sjogren's disease (DAHLIAS): a randomised, phase 2, placebo-controlled, double-blind trial. Lancet. 2025 Nov 22;406(10518):2435-2448. doi: 10.1016/S0140-6736(25)01430-8. Epub 2025 Oct 24.
Даты записи исследования
Изучение основных дат
Начало исследования (Действительный)
Первичное завершение (Действительный)
Завершение исследования (Действительный)
Даты регистрации исследования
Первый отправленный
Впервые представлено, что соответствует критериям контроля качества
Первый опубликованный (Действительный)
Обновления учебных записей
Последнее опубликованное обновление (Действительный)
Последнее отправленное обновление, отвечающее критериям контроля качества
Последняя проверка
Дополнительная информация
Термины, связанные с этим исследованием
Дополнительные соответствующие термины MeSH
- Заболевания опорно-двигательного аппарата
- Заболевания полости рта
- Стоматогнатические заболевания
- Артрит
- Заболевания суставов
- Ревматические заболевания
- Заболевания соединительной ткани
- Аутоиммунные заболевания
- Заболевания иммунной системы
- Глазные болезни
- Артрит, Ревматоидный
- Ксеростомия
- Заболевания слюнных желез
- Синдром сухого глаза
- Заболевания слезного аппарата
- Заболевания кожи и соединительной ткани
- Синдром Шегрена
Другие идентификационные номера исследования
- CR109062
- 2021-000665-32 (Номер EudraCT)
- 80202135SJS2001 (Другой идентификатор: Janssen Research & Development, LLC)
Планирование данных отдельных участников (IPD)
Планируете делиться данными об отдельных участниках (IPD)?
Описание плана IPD
The data sharing policy of Johnson & Johnson Innovative Medicine is available at www.innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu.
Информация о лекарствах и устройствах, исследовательские документы
Изучает лекарственный продукт, регулируемый FDA США.
Изучает продукт устройства, регулируемый Управлением по санитарному надзору за качеством пищевых продуктов и медикаментов США.
Эта информация была получена непосредственно с веб-сайта clinicaltrials.gov без каких-либо изменений. Если у вас есть запросы на изменение, удаление или обновление сведений об исследовании, обращайтесь по адресу register@clinicaltrials.gov. Как только изменение будет реализовано на clinicaltrials.gov, оно будет автоматически обновлено и на нашем веб-сайте. .